Education
About Us
Working with TipRanks
Follow Us
Prothena Corporation (PRTA)
:PRTA
PRTA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.32 - $18.88
Previous CloseN/A
Volume58.73K
Average Volume (3M)796.81K
Market Cap
$540.99M
Enterprise Value-$34.92M
Total Cash (Recent Filing)$371.44M
Total Debt (Recent Filing)$9.78M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Oct 30, 2025EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.34
Shares Outstanding53,829,930
10 Day Avg. Volume808,570
30 Day Avg. Volume796,813
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.06
Enterprise Value/Revenue-3.38
Enterprise Value/Gross Profit-3.70
Enterprise Value/Ebitda0.14
Forecast
1Y Price Target
$13.00Price Target Upside29.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe CLEOPATRA trial for coramitug in ATTR cardiomyopathy signifies a design that captures both mortality and morbidity, differentiating the asset from the landscape.
Research And DevelopmentFavorable amyloid plaque reduction was observed alongside ARIA rates comparable to placebo, suggesting that PRX012 can exert therapeutic effects at lower concentrations without exacerbating risk.
Strategic PartnershipsProthena's arrangement with partners offers asymmetric upside that is not reflected in the current valuation.
Bears Say
Market RecognitionThe market is ignoring two partnered Phase 3 programs and a partnered Phase 2 program with blockbuster potential.
Market ValuationRecent updates reinforce the thesis that PRTA is currently undervalued, with the market assigning zero credit to two late-stage partnered assets targeting multi-billion dollar markets.
Prothena News
PRTA FAQ
What was Prothena Corporation’s price range in the past 12 months?
Prothena Corporation lowest stock price was $4.32 and its highest was $18.88 in the past 12 months.
What is Prothena Corporation’s market cap?
Prothena Corporation’s market cap is $540.99M.
When is Prothena Corporation’s upcoming earnings report date?
Prothena Corporation’s upcoming earnings report date is Oct 30, 2025 which is in 17 days.
How were Prothena Corporation’s earnings last quarter?
Prothena Corporation released its earnings results on Aug 04, 2025. The company reported -$2.34 earnings per share for the quarter, missing the consensus estimate of -$1.254 by -$1.086.
Is Prothena Corporation overvalued?
According to Wall Street analysts Prothena Corporation’s price is currently Undervalued.
Does Prothena Corporation pay dividends?
Prothena Corporation does not currently pay dividends.
What is Prothena Corporation’s EPS estimate?
Prothena Corporation’s EPS estimate is -0.69.
How many shares outstanding does Prothena Corporation have?
Prothena Corporation has 53,829,930 shares outstanding.
What happened to Prothena Corporation’s price movement after its last earnings report?
Prothena Corporation reported an EPS of -$2.34 in its last earnings report, missing expectations of -$1.254. Following the earnings report the stock price went up 1.297%.
Which hedge fund is a major shareholder of Prothena Corporation?
Currently, no hedge funds are holding shares in PRTA
Prothena Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.00 (29.35% Upside)
$13.00 (29.35% Upside)
Hedge Fund Trend
Increased
By 34.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.4%
Last 30 Days ▼ 10.5%
Last 30 Days ▼ 10.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.10%
12-Months-Change
Fundamentals
Return on Equity
-66.85%
Trailing 12-Months
Asset Growth
-38.18%
Trailing 12-Months
Company Description
Prothena Corporation
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
PRTA Stock 12 Month Forecast
Average Price Target
$13.00
▲(29.35% Upside)
Technical Analysis
Lexicon Pharmaceuticals
―
Xoma
―
Zevra Therapeutics
―
Corvus Pharmaceuticals
―
Alumis Inc.
―
Ownership Overview
24.47% Insiders
26.44% Mutual Funds
22.96% Other Institutional Investors
20.33% Public Companies and
Individual Investors